Strategic Backing Strong pharma investor backing and collaboration history signals readiness for large-scale deals. Sanofi participated in the Series B; Roche Venture Fund is an investor; Genentech collaboration exists, indicating potential for co development or licensing of COURs CNP platform in autoimmune diseases.

Platform Licensing COURs proprietary CNP platform enables antigen-specific immune tolerance with a disease-modifying, non-suppressive mechanism, creating licensing or co-development opportunities with global pharma to apply the platform across PBC, T1D, MG, celiac, and other autoimmune indications.

Autoimmune Portfolio A diversified pipeline across four indications provides multiple collaboration targets and reduces risk, with potential for trial services, biomarker collaborations and co-development in niche autoimmune markets.

Funding Momentum A $50 million Series B in 2026 signals growth runway to accelerate clinical expansion and manufacturing scale-up, enabling milestone-driven partnerships and strategic investments with larger partners.

Market Positioning First-in-class disease-modifying approach targeting root causes with non-suppressive immune modulation offers a compelling value proposition for payer engagement, HTA pathways and early access programs.